Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial

Autor: T. M. L. Tong, M. K. van der Kooij, F. M. Speetjens, A. R. van Erkel, R. W. van der Meer, J. Lutjeboer, E. L. van Persijn van Meerten, C. H. Martini, R. W. M. Zoethout, F. G. J. Tijl, C. U. Blank, M. C. Burgmans, E. Kapiteijn

Publikováno v: Trials, Vol 23, Iss 1, Pp 1-13 (2022)

Abstract Background While immune checkpoint inhibition (ICI) has revolutionized the treatment of metastatic cutaneous melanoma, no standard treatments are available for patients with metastatic uveal melanoma (UM). Several locoregional therapies are

Externí odkaz: https://doaj.org/article/02b20954af9940f199b502ac5e14eeeb

Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study

Autor: Saskia Santegoets, Sjoerd H van der Burg, Noel de Miranda, Els Verdegaal, Monique K van der Kooij, Marten Visser, Caroline van der Minne, Linda de Bruin, Pauline Meij, Anton Terwisscha van Scheltinga, Marij J Welters, Inge Roozen, Gerrit Jan Liefers, Ellen Kapiteijn

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)

Background Adoptive cell therapy (ACT) with tumor-reactive T cells has shown consistent clinical efficacy. We evaluated the response to ACT in combination with interferon alpha (IFNa) preconditioning in patients with stage IV metastatic melanoma, mos

Externí odkaz: https://doaj.org/article/8a791317a23f42e9bd1f266c841518cc

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Figure S6 from Evolutionary Routes in Metastatic Uveal Melanomas Depend on MBD4 Alterations

Autor: Marc-Henri Stern, Pascale Mariani, Sergio Roman-Roman, Joshua J. Waterfall, Gaëlle Pierron, Nathalie Cassoux, Sophie Piperno-Neumann, Sarah Tick, Marc Putterman, Rémi Dendale, Vincent Servois, Raymond L. Barnhill, Sophie Gardrat, Sieta Gassama, Ellen Kapiteijn, Monique K. Van der Kooij, Khadija Ait Rais, Benjamin Marande, Odette Mariani, Sylvain Baulande, Samar Alsafadi, Alexandre Houy, Lenha Mobuchon, Manuel Rodrigues

Supplementary figure 6 - Comparisons of CCFs between samples including inter- and intra-metastatic comparisons in MBD4pro samples.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e43d9268e6257955aebe5fc73ffe128
https://doi.org/10.1158/1078-0432.22471973

Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study

Autor: Monique K. van der Kooij, Arjen Joosse, Karijn P. M. Suijkerbuijk, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Marye J. Boers-Sonderen, Alfonsus J. M. van den Eertwegh, Jan Willem B. de Groot, John B. A. G. Haanen, Geke A. P. Hospers, Djura Piersma, Rozemarijn S. van Rijn, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Hans M. Westgeest, Michel W. J. M. Wouters, Olaf M. Dekkers, Ellen Kapiteijn

Publikováno v: British Journal of Cancer, 128, 5, pp. 707-710
British Journal of Cancer. SPRINGERNATURE
British Journal of Cancer
British Journal of Cancer, 128(5), 707-710. Nature Publishing Group
British Journal of Cancer. Nature Publishing Group
British Journal of Cancer, 128, 707-710

Treatment with targeted therapy and immune checkpoint inhibitors has significantly improved survival of patients with advanced melanoma. Unfortunately, a large proportion of patients are either primary non-responders or will eventually develop second

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45482662de6d44c01822ae7e8821564d
https://doi.org/10.1038/s41416-022-02088-8